Annual Securities Report — FY2025
What ASKA Pharmaceutical Holdings Co.,Ltd. reported for the period from 2025-04-01 to 2026-03-31.
Filed 2026-06-19View the original on EDINET
How much it says
68Detailed
What moved here
38named for the first time
Its own wording
57terms
Which filing this is
16/ 16newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the period, revenue increased, as did ordinary profit and net income attributable to owners of the parent. Overseas Operations was also newly added as a reporting segment after Ha Tay Pharmaceutical Joint Stock Company in Vietnam became a consolidated subsidiary.
Komori's summary of this document, not the document's own words.68Detailed
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 38 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
76
Very detailed
91
Very detailed
73
Detailed
75
Very detailed
90
Very detailed
68
Detailed
27
Almost nothing
62
Detailed
60
Detailed
55
Typical
50
Typical
R&D spend71億円Money spent making new things.
Cash left over6億円Cash from the business, less what went into equipment.
Spent on equipment27億円Plants, machines — things meant to last.
Employees1,611Headcount at the end of this period.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.